Analysts Set Sotera Health Company (NASDAQ:SHC) PT at $17.20

Shares of Sotera Health Company (NASDAQ:SHC) have been given an average rating of “Hold” by the six research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $17.40.

Several equities analysts recently commented on SHC shares. Barclays increased their price objective on shares of Sotera Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Wednesday, November 5th. JPMorgan Chase & Co. lifted their target price on shares of Sotera Health from $14.00 to $16.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Piper Sandler raised their price target on shares of Sotera Health from $15.00 to $17.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Sotera Health in a research note on Friday, October 31st. Finally, Wall Street Zen raised Sotera Health from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 16th.

Sotera Health Trading Up 0.4%

SHC opened at $15.74 on Tuesday. The stock has a market capitalization of $4.47 billion, a price-to-earnings ratio of 82.85 and a beta of 1.82. The company has a quick ratio of 2.18, a current ratio of 2.38 and a debt-to-equity ratio of 4.04. Sotera Health has a twelve month low of $9.53 and a twelve month high of $17.78. The company has a 50-day simple moving average of $16.09 and a 200 day simple moving average of $13.84.

Sotera Health (NASDAQ:SHC) last released its earnings results on Friday, August 8th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.17 by $0.03. The firm had revenue of $294.34 million for the quarter, compared to analyst estimates of $275.81 million. Sotera Health had a net margin of 4.82% and a return on equity of 43.69%. The business’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same period last year, the firm earned $0.19 EPS. Analysts predict that Sotera Health will post 0.61 EPS for the current fiscal year.

Insider Activity at Sotera Health

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 8,000,000 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $15.11, for a total value of $120,880,000.00. Following the completion of the sale, the director owned 41,215,301 shares of the company’s stock, valued at approximately $622,763,198.11. This trade represents a 16.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Michael P. Rutz sold 126,611 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $16.38, for a total transaction of $2,073,888.18. Following the transaction, the insider owned 450,204 shares in the company, valued at approximately $7,374,341.52. The trade was a 21.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 20,126,611 shares of company stock valued at $304,273,888 in the last three months. Corporate insiders own 55.12% of the company’s stock.

Hedge Funds Weigh In On Sotera Health

Several large investors have recently bought and sold shares of SHC. Ameritas Investment Partners Inc. lifted its position in shares of Sotera Health by 9.7% during the third quarter. Ameritas Investment Partners Inc. now owns 33,014 shares of the company’s stock valued at $519,000 after purchasing an additional 2,920 shares in the last quarter. CenterBook Partners LP purchased a new stake in Sotera Health in the 3rd quarter valued at about $1,228,000. Vanguard Group Inc. boosted its stake in shares of Sotera Health by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 16,471,792 shares of the company’s stock worth $259,101,000 after buying an additional 1,561,282 shares during the last quarter. Northwestern Mutual Investment Management Company LLC grew its holdings in shares of Sotera Health by 14.7% in the third quarter. Northwestern Mutual Investment Management Company LLC now owns 39,254 shares of the company’s stock valued at $617,000 after acquiring an additional 5,030 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Sotera Health by 1.4% in the third quarter. JPMorgan Chase & Co. now owns 237,576 shares of the company’s stock valued at $3,737,000 after acquiring an additional 3,323 shares in the last quarter. 91.03% of the stock is currently owned by institutional investors.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.